Americana Partners LLC Grows Stock Holdings in PROCEPT BioRobotics Co. (NASDAQ:PRCT)

Americana Partners LLC grew its position in shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT) by 26.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 23,525 shares of the company’s stock after purchasing an additional 4,875 shares during the period. Americana Partners LLC’s holdings in PROCEPT BioRobotics were worth $1,894,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Values First Advisors Inc. purchased a new stake in PROCEPT BioRobotics in the third quarter worth approximately $27,000. Raleigh Capital Management Inc. purchased a new stake in shares of PROCEPT BioRobotics in the 4th quarter valued at $32,000. Wilmington Savings Fund Society FSB bought a new position in shares of PROCEPT BioRobotics during the 3rd quarter valued at $64,000. Canton Hathaway LLC purchased a new position in PROCEPT BioRobotics in the 3rd quarter worth $66,000. Finally, Nisa Investment Advisors LLC lifted its stake in PROCEPT BioRobotics by 178.3% in the third quarter. Nisa Investment Advisors LLC now owns 1,113 shares of the company’s stock worth $89,000 after purchasing an additional 713 shares during the last quarter. 89.46% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In related news, CEO Reza Zadno sold 26,420 shares of PROCEPT BioRobotics stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $92.57, for a total transaction of $2,445,699.40. Following the sale, the chief executive officer now directly owns 205,605 shares in the company, valued at $19,032,854.85. The trade was a 11.39 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Alaleh Nouri sold 28,092 shares of the stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $97.13, for a total value of $2,728,575.96. Following the completion of the transaction, the executive vice president now owns 52,472 shares of the company’s stock, valued at approximately $5,096,605.36. This trade represents a 34.87 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 107,355 shares of company stock valued at $10,327,788. Corporate insiders own 17.40% of the company’s stock.

PROCEPT BioRobotics Stock Performance

NASDAQ:PRCT opened at $67.61 on Tuesday. The company has a quick ratio of 5.07, a current ratio of 6.02 and a debt-to-equity ratio of 0.21. PROCEPT BioRobotics Co. has a twelve month low of $45.20 and a twelve month high of $103.81. The stock has a market cap of $3.53 billion, a P/E ratio of -34.67 and a beta of 1.03. The firm’s fifty day simple moving average is $78.51 and its 200 day simple moving average is $79.80.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the company. Truist Financial reiterated a “buy” rating and issued a $105.00 price objective (up previously from $95.00) on shares of PROCEPT BioRobotics in a report on Wednesday, October 30th. Wells Fargo & Company reiterated an “overweight” rating and issued a $112.00 price objective on shares of PROCEPT BioRobotics in a research report on Tuesday, December 3rd. Jefferies Financial Group started coverage on shares of PROCEPT BioRobotics in a report on Thursday, November 14th. They issued a “hold” rating and a $95.00 target price on the stock. Finally, Morgan Stanley started coverage on shares of PROCEPT BioRobotics in a report on Monday, December 2nd. They set an “overweight” rating and a $105.00 price target for the company. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $97.86.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).